915924-79-7

Usage

Uses

Used in Pharmaceutical Research and Development:
CHEMBRDG-BB 4014416 is used as a research compound for exploring its potential in the development of new pharmaceuticals. Its unique molecular structure, which includes chlorine and nitrogen atoms, suggests that it may interact with biological systems in ways that could be beneficial for treating certain conditions or diseases.
Used in Drug Discovery:
In the drug discovery process, CHEMBRDG-BB 4014416 is used as a lead compound to identify its possible pharmacological properties. Researchers are interested in understanding how CHEMBRDG-BB 4014416 interacts with biological targets, which could provide insights into its therapeutic potential and guide the design of more effective drugs.
Used in Toxicology Studies:
CHEMBRDG-BB 4014416 may also be used in toxicology studies to evaluate its safety profile. Understanding the compound's potential toxic effects is crucial for assessing its suitability for use in humans and for determining the appropriate dosages and administration routes.
Used in Chemical Synthesis:
As an organic compound, CHEMBRDG-BB 4014416 could be used in chemical synthesis processes to create new compounds with potentially novel properties. Its reactivity and the presence of functional groups may allow for the formation of new chemical entities that could have applications in various fields, including materials science and pharmaceuticals.
Note: Since the specific applications and uses of CHEMBRDG-BB 4014416 are not detailed in the provided materials, the above uses are speculative and based on the general roles that similar organic compounds with potential therapeutic applications might serve in the pharmaceutical industry. Further research and experimentation would be required to confirm these potential uses.

InChI:InChI=1/C9H7BrN2O/c1-13-9-7-4-6(10)2-3-8(7)11-5-12-9/h2-5H,1H3

Upstream product

• 52727-57-8 5-bromo-2-aminobenzoic acid methyl ester 
• 134-20-3 2-carbomethoxyaniline 
• 32084-59-6 6-bromoquinazolin-4(3H)-one 
• 38267-96-8 6-bromo-4-chloroquinozoline 
• 124-41-4 sodium methylate 

Relevant academic research and scientific papers

SUBSTITUTED IMIDAZOLES FOR THE INHIBITION OF TGF-BETA AND METHODS OF TREATMENT

This disclosure relates to low molecular weight substituted imidazoles that inhibit the TGF-b signaling pathway. More specifically, this disclosure relates to methods of using said imidazoles for the treatment of diseases related to the TGF-b signaling pathways including, but not limited to, atherosclerosis, Marfan syndrome, Loeys-Dietz syndrome, obesity, diabetes, multiple sclerosis, keratoconus, idiopathic pulmonary fibrosis, Alzheimer's Disease, chronic kidney disease, and scleroderma.

1,2,4-TRIAZINE-3-AMINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF IN MEDICINE

The present invention relates to a 1,2,4-triazine-3-amine derivative, a preparation therefor, and use thereof in medicine. Specifically, the present invention relates to a 1,2,4-triazine-3-amine derivative as represented by general formula (I), a preparation method therefor, a pharmaceutical composition comprising the derivative, and use thereof as a therapeutic agent, in particular as an A2a receptor antagonist, and use thereof in the preparation of a medicament for treating a condition or disorder that is ameliorated by means of inhibition of the A2a receptor, each substituent in general formula (I) being same as defined in the description.

HETEROCYCLIC SULFONAMIDES AS RAF INHIBITORS

Compounds of Formula (I) are useful for inhibition of Raf kinases. Methods of using compounds of Formula (I), stereoisomers, tautomers and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.

NEW CHEMICAL COMPOUNDS

The present invention encompasses compounds of general formula (1) wherein the groups R1 to R4, Qa, Qb, QH, L and n are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, pharmaceutical preparations which contain such compounds and their use as medicaments.

HETEROCYCLIC CARBOXYLIC ACID AMIDES AS PDK1 INIHIBITORS

The present invention encompasses compounds of general formula (1) wherein the groups R1 to R4, Qa, Qb, QH, L and n are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, pharmaceutical preparations which contain such compounds and their use as medicaments.